What is the role of receptor activator of nuclear factor-kappaB ligand (RANKL) in the treatment of osteogenesis imperfecta (OI)?

Updated: Feb 24, 2020
  • Author: Manoj Ramachandran, MBBS, MRCS, FRCS; Chief Editor: Harris Gellman, MD  more...
  • Print
Answer

A preclinical study demonstrated that inhibition of receptor activator of nuclear factor-kappaB ligand (RANKL) improves density and some geometric and biomechanical properties of the oim/oim mouse bone but does not decrease fracture incidence when compared with placebo. [40]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!